210 related articles for article (PubMed ID: 7372443)
1. Endocrine manipulation of the Dunning prostatic adenocarcinoma.
Shessel FS; Block NL; Stover B; Claflin A; Malinin TI; Politano VA
Invest Urol; 1980 May; 17(6):529-33. PubMed ID: 7372443
[TBL] [Abstract][Full Text] [Related]
2. Flow cytometric analysis of the response of the R3327-G rat prostatic adenocarcinoma to endocrine manipulation.
Pollack A; Bagwell CB; Block NL; Irvin GL; Claflin AJ; Stover BJ
J Surg Oncol; 1981; 18(4):389-98. PubMed ID: 7321568
[TBL] [Abstract][Full Text] [Related]
3. Hormonally responsive versus unresponsive progression of prostatic cancer to antiandrogen therapy as studied with the Dunning R-3327-AT and -G rat adenocarcinomas.
Isaacs JT
Cancer Res; 1982 Dec; 42(12):5010-4. PubMed ID: 6215981
[TBL] [Abstract][Full Text] [Related]
4. A rat prostatic adenocarcinoma as a model for the human disease.
Müntzing J; Kirdani RY; Murphy GP; Sandberg AA
Invest Urol; 1979 Jul; 17(1):37-41. PubMed ID: 447485
[TBL] [Abstract][Full Text] [Related]
5. Concepts in prostatic cancer biology: Dunning R-3327 H, HI, and AT tumors.
Isaacs JT; Weissman RM; Coffey DS; Scott WW
Prog Clin Biol Res; 1980; 37():311-23. PubMed ID: 7384091
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer.
Smolev JK; Heston WD; Scott WW; Coffey DS
Cancer Treat Rep; 1977; 61(2):273-87. PubMed ID: 872132
[TBL] [Abstract][Full Text] [Related]
7. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
8. The effects of castration, testosterone and oestrogen on epithelial and stromal growth and morphology of the Dunning (R3327H) prostatic adenocarcinoma.
Damber JE; Landström M; Bergh A; Tomic R
Scand J Urol Nephrol Suppl; 1988; 110():145-8. PubMed ID: 3187402
[No Abstract] [Full Text] [Related]
9. Experimental models for the study of prostatic adenocarcinoma.
Smolev JK; Coffey DS; Scott WW
J Urol; 1977 Jul; 118(1 Pt 2):216-20. PubMed ID: 875219
[TBL] [Abstract][Full Text] [Related]
10. In vivo selection of androgen-insensitive cells in R3327-G rat prostate tumors: diethylstilbestrol diphosphate treatment versus orchiectomy.
Pollack A; Block NL; Stover BJ; Irvin GL; Fuentes MP; Claflin AJ; Malinin TI
J Natl Cancer Inst; 1983 May; 70(5):907-14. PubMed ID: 6573535
[TBL] [Abstract][Full Text] [Related]
11. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
[TBL] [Abstract][Full Text] [Related]
12. Response of the Dunning R3327H prostatic adenocarcinoma to radiation and various chemotherapeutic drugs.
Mador D; Ritchie B; Meeker B; Moore R; Elliott FG; McPhee MS; Chapman JD; Lakey WH
Cancer Treat Rep; 1982 Oct; 66(10):1837-43. PubMed ID: 6889915
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial damage produced by estradiol valerate in the Dunning (R3327H) rat prostatic adenocarcinoma: a preliminary report.
Arcadi JA; Poolsawat S
Prog Clin Biol Res; 1981; 75B():329-34. PubMed ID: 7323100
[No Abstract] [Full Text] [Related]
14. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
[TBL] [Abstract][Full Text] [Related]
15. Hormonal therapy: the benefits of postponed initiation.
Cockburn AG
Urology; 1984 Nov; 24(5 Suppl):24-6. PubMed ID: 6388093
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
17. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat.
Brändström A; Westin P; Bergh A; Cajander S; Damber JE
Cancer Res; 1994 Jul; 54(13):3594-601. PubMed ID: 8012987
[TBL] [Abstract][Full Text] [Related]
18. Response to chemically induced prostatic tumors in rats to stilbestrol and orchiectomy.
Butz GW; Cooper TP; Barham R; Ansell JS
Surg Forum; 1976; 27(62):590-2. PubMed ID: 1019987
[No Abstract] [Full Text] [Related]
19. Status of the treatment of prostatic carcinoma--1964.
Prout GR
Proc Natl Cancer Conf; 1964; 5():309. PubMed ID: 5889426
[No Abstract] [Full Text] [Related]
20. Expression of transforming growth factor-beta 1 in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatment.
Lindström P; Bergh A; Holm I; Damber JE
Prostate; 1996 Oct; 29(4):209-18. PubMed ID: 8876704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
